83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through ...
Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that updated clinical data on its investigational therapy, ...
Technology Adoption Program (TAP) program success demonstrates the ability of Cellares’ IDMO Smart Factory to automate, lower costs and scale out manufacturing for Cabaletta Bio’s clinical-stage CAR T ...
Agreement positions Cellares as a long-term commercial manufacturing partner for rese-cel, enabling thousands of batches per year at a cost per batch that is among the lowest in the industry Cellares’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results